HUE031624T2 - Piridon származék - Google Patents

Piridon származék Download PDF

Info

Publication number
HUE031624T2
HUE031624T2 HUE13743985A HUE13743985A HUE031624T2 HU E031624 T2 HUE031624 T2 HU E031624T2 HU E13743985 A HUE13743985 A HU E13743985A HU E13743985 A HUE13743985 A HU E13743985A HU E031624 T2 HUE031624 T2 HU E031624T2
Authority
HU
Hungary
Prior art keywords
group
compound
oxo
added
room temperature
Prior art date
Application number
HUE13743985A
Other languages
English (en)
Inventor
Hitoshi Ohki
Masahiro Ota
Kosuke Takeuchi
Hideaki Watanabe
Akitake Yamaguchi
Yoshihiro Shibata
Yuichi Tominaga
Takeshi Jimbo
Keijiro Kobayashi
Katsuhiro Kobayashi
Daisuke Fukatsu
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of HUE031624T2 publication Critical patent/HUE031624T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (3)

  1. SgafeMiiM :ymm&amp; ^ ^ '? ^ 1 ^ ^
    vshoi i; k.'pte; Í5 * A repramtii «« ^oportet vagy hál i»p he*m&amp;6» ropod íilKk az Λ-to köt«*» amm* csoport ox <(>: mKogé?)^»?^ teruot skksa pata hete vu »ok egyuteaoa aq>e*, R' K-ntc/catjl r Μ,; sikk cx-Sxxk>k ar.wiw*k kteu egv sisgy liialai*xmty ki « ^«,v* Ρ^ϊ,ηλι te *ni m M vas vila«,va i ν ·|>οηίκ·Ι 2, huervaoi c^P«« m ^iynck tetei m *m robb xMh* W miy kî van választva C;opoíiW->i à, vagy aiorog.ts arax. « g te «\ JU ,mx -'.tot. anxb.xk sehe« sg> χ rp több xeuteteiuxux." ^ ü v'f J.t« a Cst>' r VI 1 * -X Jk χ » b 'Λ X a ;x ' v 'V k te : cp x K*h v^bti« »se,· mcfy te \\m vateateta « kö vu kente tevői: hteogus atom οχ hteroul -ΟΟΝίΓίΓ», stml Rv te R* omtttegyte Riggetlmsi «f*«w»àl C rC* aikii a^wnm. amehoek tetet egy vágy rbbb afe»« aütev te vxt! vtiaurtva ,Mitesäkcudk kötete halogén atom, CrC\ alkosd csoport és Ηί4:υχϋ vsrrpxt, vagy Mteg&amp;- stoaöt* vagy E"v és·. 0" a mmsg^áí©ö^i? urMyto kötmk, ;Μμμ?ΜΙ Mtp lefesödyÖÄ -saepÄiafeâîâk sâPelyrîtexiélste argy -vagy br m\ *Mmm&amp; « köveüí«zbk MiàU; teîo#« »rom. CrC, »s.ks.Uxopx'!X Cs-< '·· aikoxs söpört és ibhoateUxopost. ukteaiksi i.'xogortou anx-.iyïvte teher egy vagy robb notevikauve. assoie h vao tálasba ( xöpc-rthoí 2, femi •vopostog ^^iyssek:Mbél'«#vVá'gy'::Í#b: :émg|y ki van választva <::te|orÉbÍ te heruonb .•v'.íxxfVí aoa'bwi, it hu egy χ «ρ kte» χ··»' xinivv', uute k tan xirhx. x5 t xtV'thite 2, χ-tete hidrogén ateuxte 0 Vísib:voo:uov A-n, ahoi« rapsvzsthik «gésa sakmoîi iterôt teig, èvmkMegyik i:? léiéi susnos vggy kaibiitegi rhMfegyskksk fea s keÄ vagy több év ssgseasmilíí CrC§ alkiteteparrog g|yoels tetei tory vagy u?bb sávl.víHro'.'ö?'.: as-aeh- kt vao telavíata í'aoponte'i ?, C:-f .x tete-xl txoros-ä-tg íi-neiyxeR isikéi íí&amp;v vsssy ibite SKrsbskiiRssrvsí.. aptty-ikr varr ysiksKrvg :r tesvarkskbk aèteil: iteibgur 4itex es: ibiRteîkd assigork Cx-C; sÜsibks :teb|ten&amp;g aovtensk lakai egy vágy ibbh aaai>rysRasayv, arasiy k:> Vag vàlâsgrya R kővsítewk koabi: hakjgéa soan te a bidroxb cxopors. tedopte raoi'o.’-ssy hidroxb cxopori, í' V x -y ίχ h '5 m x r \ tat ^ P ' * x * !x X\ ^rt v χ χ'!ί vibax.ova i ‘sopcîrîbt'i L -OR’ -i ahoi kl tzpi'cvzntäl t r< '; aikii α«>ρν!Ί"ί. unaxu-sk Rise? egy tasy kteb XilxOÎÎ X- 0 te VS í VÏ , xXx SO'xV y x j \ XV !l"\ii «‘ Iffl οχ kv.tex «sopöfR ilirmavh#:.:M§èi;;hÂré8Mé«lfeÔ SPbf sftöí>. afgs|y»ok Mag agy vagy k>bb sgabaasirogfisg: aarviy &amp;* vsa tàia^K* va a köveíte-^k tetei·}: haingérv anno i.'rC, slkií oxoporr te a hKiwaii osopon. vagy hidege« zxvxx, k-C- aîl iiüo V v,\» - ^'hoek uht! νκ,χ \-N» siuhv sms^e, afi»eh h \ae s kővetkezők közül. Ivssixgexi ak»m è,5 iïïÎÏrsX'-ï esigív··?, veg> hidrogén aiotîi. R" wpveainiià} hüchOges alomét. v&amp;gx C;-*.k csopoitos. asS«i|psife wyfÜffÊfàh «M$iaüue«pe, amely ki van választva 0*»p«rt&amp;6i i, W tqwezetâlâ! C-R4·* vagx «sirogètx aiomok tshoi R* svpïxîzesïtà? C ; ('<. <ι'&amp;χ1 i3<>fx>n<x amelyrxek lebxx "sv vagy sèshh swabsssttwease. am« ly ki va« vatsiastY« í3se>pxs'tb*l ! > ί.\·1 >\ aikesx? stsei|>?stí*'g stselyxiek k'bes egg vagy több mibszsilttetase* .gKiely ki V® vlktsztm à következők közük: C: -Cs alkoss csoport, '-¾¾¾¾^¾ asm# hi<!íí>xx? csoport,. dklosikil íjNOponok atsxeiynek lehet égy vágy több sztjhszziisxesxe. amcb ki van vábmtva Cpoportbói 3, akloaikenii ekefotksk afekiyÄ fekd egy vagy jobb szubsatíüKtase, sííh-W k» vtm választva CSopotl x h«i«rovikkáiikii cs<>gíirí:oi: asnelysíek lehet egy vágy t'K Siii"vöt*X, Ί»^ η Ή \ » s ? ν» » t V\ ïksl ' lii \ K0»( v^kvpi'U e X„'Kt » v le xt xv x vag^ Mbh senN/ox es»^ ^melx kx xtxo taL- Ue 5 -xopo;őx>' » ;rö s Oporto?' am '\ο·'\ k x i ogt '8gx t<Ov s * * ο '! k v< s Xx " s V >\‘ " h t ' ií XX kk V tx'vtAs . ? ' s Ό x ;<íbb szukezhüsesív. nmAy h van vaisáztta «. vxtptxttból 3 isabge« atomot. vagy a Imfcftgen ahtrnk és ik : tő|R«;zeíí?á!: C kk·: vsgy rskogéíXtawiKs... vagy amvak νζμ»; Caopor t:· itólsgsn : aííxmök: . KFnF.S'! «n ·€ΠΝ'ΚλΚ&amp;··· ahol RÄ Μ R’s «ihiiiegxtk isggctkttyl repöz&amp;mtsf €rC| slfcfí cvoponot. amelynek lőhet egy vagy söbh sxahsmmense, aateiy kt vsa tdksztvs «ö£§vdteÄ-ÄÖi?· tsalogè?? ato»?. Í\-C\ «ücoxt csoport és hídroKsi csoport, vagy kiőstígte atotti. vagy FA és R* egyik? 8 mtrogémexmmJ&amp;h amcíyfeeA kötitek. btes-hél tsgtls»rtÄloÄi csoport«» -8ik»il{8toW.a^lyMk'M®? gg;v vsgy iebfe ^fessÄnassiv a»?«iy ki vaa vâ1a\??v» « fckveíU'^k közűi: habgvn atom. Cr<'·. bk?i as^'xrl, Cí'Cí aikesi <;sí?p;>f·? *s .hidrcxíl csagWE. n'íK1'. ák-xi í#s 'fvyx'í'^xsxi «. Λ ^ .x.kö esog^ítiv;, xmxHxs 's iek'S sí, ', sxolí's sbví««v'x\e, ímv'h kí \^;' x.-ö-.^-öx-.s a I ονοηκ·?$Γkőről ?3·-Γ ilk-\í h,>i<'>g'?s ;síoííí és Seöx-sxxi esopisrg * Ό" Kl U Xi »VtC X ' k i'áik . o Xi'-sti'X XiSWîs's >s ti , > v > l»^ '< lïKwsiïiVilSiï. «*88iî> k vàiî s.ila-tm.i 3 kC'Xi'tkx-zéik. kô?vi'. «aRx^sx amtn, ?3;-k .> alkü irsoîxxx?: ès iííásssö. s5sap5i1;yvsfy kxkegé?? ôîxïitïO!:. 3fx? v'vxvîi'·» ,î5K?>sxx'k i-'leî vex xagv kxl*k s/u?>szâxîxivjxse. esxífív ki s.îxs X xix\:-ix ï < » x x?ks? cso?>x>nb<ik ai-îvhî'ü'k k-kx: egy xagy ri-Hb si:isbs,;-iixivxm\ imsdy ks vas v:H«viv»i a kővetkezők kózxö: hxk'géïx xi-tíix: X-;; hi'ittï'iii cv<'px>rtf CS'C. .ïiko.x·i < ;':xgon, o>:o Xi.i.xgori x-ï lisk.g.yij «ux-x beisarwirix esopoïi, .iiXKxlysxx'k k-'-χχϊ· xtgy w.g>' több szvhvzövvicjxvzv amely ki vats vátasxlva a következők közük 0rCt, askö csvports amei'vnbk ívti?cí egy vsgy több sx«bs?ti^ös% amely; b-:«a.ívétostv» következők közük: hstlogès? atomos tiseis'ixxxl x^x'px'îS· í-VC.si?Ík<>si íssxgi'st. vw$%xspon. hkiroxl? esöpört ev haiogéa ssessg hésxxstx-kíét tagú eikloaikü esv-persi·;, asxieiytiek lehel egy \agy több xczuhszsxíumtw, amely ki v-us x'ükíssktvx? s'köveikevök kx'Z«l CVC-aikü x'jsopxmból. amslymek lehel egy vagy több .sreb^ztittiet?.'^·. zsstek· v NS ^ ' s, Xs ki xk\e^ t'es's"' bv30x< s' XXX V X skxV'v '«X 'Si -> x< tsíxlx'isgö i:sx>i>i'x't és hakxgexi vüx'íxí v* iîlrossî hîiî tegû heu.'PViklos&amp;j} <5M.^x»n<»k axtsdypek lebet spy vagy t<SU> s£afesam«en».«k asndy ks UlXVîküsdW i !'< ; 3ÎUÎ CSOjViîlK^ >î5ïî«hWk k'kiit Cp feVi'b SCOpXOiJOiiXC iSSiX'lY k: \a« 'ahiVpc akbvs&amp;p&amp;k kôxül: balogé« atonies Jadeoxsl:-çsoi>ôj%. C:-<\ alkoxl eaqgwt, oxo «««port, hkbo<ü ssopöfS êik ha logea -îîi>m. Gÿ&amp;poti 2i C'.';-C.N alàit 05»{χ·>»«κ ameiyaek lehet sgv vagy iàbfe sisgtxdUhkskih .atfieiy ..Kl. v*œ. s k0i:ää:; iiskhÄ h id «-ox I] csoport CV-Q. Alkoss os-open. ovo ΐ ί>ηρ<:Γ·.. hstköxil ssöpeíí <-s hafcph 8¾¾¾ < SvX'-s:; V l < ^ .'Rh ssp"-;Xh :s;;.. s.. '«'h U\ i. i'g\ , Λ'Ί tói "S' \;;·1"- .''t'ïïiCsSSC. víiC-\\ ki ' e5' ultoAa a kövüké >-ákK'í: < »topért 1, C;-Ci; atií v;;''pOíA, kh-C* slkiího csapattag xmeiystek seaes v'gv wsyy több s/ah^aue«*?, ataesy ks \a« váíawva a kóveRavXíh köíwlh-isalogés aíom es hxlro\äl cxopoo:. .(.'ON^R^h ahol R* ev r íhki>Rgysk ®ç$$ïkn® rzpmmt® kk-Cs *lkü csoportot. asnetyaek \\s Vcv \ !gs tok'' s c'x.cnUiC'a·.- a; lip ki '..i '.éke..-·*'« a \ xvCikc·vk kari»! t Pop a jK1»- *·!*' alkoss csoport és hnkoxtl csoport. vagy h-díoséo atom. vagy R' és R&amp; együtt- «»í&amp;lyix!®: RÁlmsk, látomiMl: ïâgâ iefeiKJcäMoalka os«por»x alfeisMssafe ïmMp%à ctebet. ^8ik &amp;*&amp;&amp; sxabsxsáaeOse, amely ki vsa válessvs a tídvsxkeshk kiihük balogé« aí<>m: CrCs a&amp;s< csapon, Cr-< >. &amp;lk>:»;i csapon <b háfco*sl csoport, -Ok' < ahol R' repcegeatál €s -Q, älkll csoportot, ssselyoek kox-5 egy vagy 1¾ amely ki v&amp;o vabrcava « k^xidkeÂôkMlîÆâ-C^Rttxj csoport, a-iloge« αΜτ» Èptcowphét tapa; ífe&amp;ttk&amp;löéíkü csoport L· bkboxü csoport* MtoPrthéï -tagú nesenKJkRs!»*·.!! e»}«iva«s: iefeet e«v va«v ïmh >. xl's »' ss rss iwmmi swn^\* x κχ\χ v » vK ' * u · 0, -k v aikiKapxii! o-i hi4u*\ií cwixxi OidràiXO avtss. cs ;líSí^rOclRfeáÉsl iesopûït sihsifSak lehet egy vsgj-ί töih: ^göR^áhhíostRí ahsviiy va« válasaítys Csopí:rib6i 3 ;|, Aa i. <g:hï>pyx: s*^rií;ii v-îgyük'î vag\ 3u»ak sója. «h<*í A le»lié» vs>o?k?í1.· 1, : Jsk:;l. v%lklx%éöy^»íwn««:-'vegyüiiéí viägy áíA^síks^Äd^'OcR*· Μ, :·Μ:ά A. ägdp|o8h>k bä!-ii:ieR ikc s^era-ik vegyüíat v«gy ansak eqia. apkP: 45 5. V, ' a\ qa-'iOkhx e\‘s vs « MaAwcdiÀii'i. >v s ^ "6. Μ H, IphtpsöíRok bársísíigífe :$máM% :vü^íM v«p *îaeâV kî *m v'UfiSZtv*^ kâvisiksxè esopodhol
    Äs ÄS; bánnék-kc ««ηή vagyálcs spilÿ \H4à;bAiamn.';n3.4· tiÂ'ïysi iôxî feSÎÎI ίρΙί:ϊ<|ϊ:ΐϊτ-S - ΐ3 |;iï?îyÜ J -Ä-:ilï3ÿSi;!ï:;iÎiÎ)-s4->£s?h;<î-> 1 ~2 iÎÎ3::û:^Çïâ^t:l1^ <4 'sll^äiils'ppiríid karbo Kamid vagy armak sója. k, Az. |y$: igénj?|>öf4sk Mrsndyfe sasdnb yngyulsti ameiÿ K44-|2A«ste--$^3yî* dksaföx à fe ns! kpsrMkv#41|femí] 4$y(4ÄlikAte»ilk4imAö -1 -(Äki %4âSïkïxsîï1)-)\4··ίΙ!!? MA^iíkbmS· kaíbnxnmni hsarokinnd g.: Λ:··· ϊ·.ί ί gí| ïïsipo î;3 ^í% bannaKikc -amdaS vygyöfeí kmfcüy«:. i^f4^.2~SíHbgn^Híj3ia^ ^^ΐ0«4^|Ι)ρΐ«^ΐΒί4^}|]ί^^ΙΙ4^'ίί1^ί^»{|ΜΗ»^1^1^,:^·0ΐ^α0Γδΐί1)«^4ν^!Μ^ψίί·ιάί84χ k&amp;rhoxaή&amp;<i bisifKikÄbd: :ίθ, Λ 9 ignnypna? saedmi kns-bdy. csn-ehnck db-nn» ddlrakem îsisiéjâ, aîbyly dâ ; -1 b Mkâk bàrmdyikbbôn run ;m;u;:va marne;; pmdbimkmS diágramksíy Mseket κν IC<í sugsrSkakik íbxdknmHvex à-; 1.44 \s He-:ugur/à>.x.à y-dit bybb®< S i. Λ y jg<.'î*ypot5f όχχϊχ kmtaiy isssxKix’k vstisxak kataktersNEiikus esatoaî dlifcakefcteogeks^l M-'k ! sP i ^ i" .6, ' ,9'i V v 2'<x! 5''*'' ''V 2·* '4 J·"*' V* W,~i' K'xsps, ' ,sîi*' i s S. d V» I ' » \v V «NV ! > Yv 'Y 'n ÏN-JÏ si ' ftV'ÏÎVë:. 13. N 0 jj. ' ï\ î< 'î! k U s' isk fV d \t k> i kiis sis'' O'O k N ' ckv Ό 4,32. «»,!<>. 13.52 18 .0. 18,54, 16.32. 20,.%«. 30/o. 2X34, 34.14, .:5.34 v* 2?.02 röntg«.r> p<sr9iiîrai«»:S I «'Il !1' !' <lsi'v 11' ' K !«(...< , n 0 'NS Í V K ÏJ.C· NNv'Î V î ' il- AI, íg*síytmii::sgerüsii krÄJf#j:a^%ß®k.:V««i5^k:'teÄ«8^lte. wsmâi·4Ϊί.2# S 3.86. 15.04. 19/6. 20.5% 22,2% 22,55. 25,82, 24JO. 24.20 4s 24,88 nki>p« p:.;nd0«k<. k· dxYrsm-xba-s. simslpd rásoK« çwgàrcâwaM (huiliœiifM'z í -= \ .54 A) b<-N»#txássö|;k|k nyerni, Μ. Λ 0. igény'.H>J',í v<e«üfl kíisisüv, asseíytsek sannak ksrísktcníi<tUkös οόννϋ dsHkikv;ov*;pkixd 50 ,'S N u, “,22 0,20, }»(.»». ϊλ n4, ϊχ“4. Γ54, 2k>4 "\ ' 'x 13 í'n 5í>,s* «"'üy.o pv'iddïi.iks'x' diágramns&amp;aá. sn«ely(?í nlí K.e. ^sspíxásvOi íÍsnllaaihoNNí. λ 1,54 A) II. Á l. jgéoyponl .verinn knsMfy, p!fil>í«N-l \cnmaSs kârâku'riSÂM'çMèss» diilakcíószögiíkoé} 20 Π,05, U,86, 15/6. 48,20. 22.0, >4.70, 25,80. >0,04, 26.20 0n 28.02 róni gen pordiíOáküó düigr&amp;mmbim, OAspiyel réz Ktí sugílaássials (&amp;u?lás»hos&amp;£ λ-«·' .1.54 Λ i besugárzással; volt pyiAVO: US. 40, sgéîïypom N?.smni krsNtsife Pïëlynek «.annak kaiuSo<»r*\»»k»«« c«ucv*> diOkskuOíaögvknd 30 5n 4,50.0,00 6/2.029 *».fO. k>,25 106" es 24,2 ' «·6»«ρ(ΐ i'osdnn.iO x s'.s »gs.«oxxb\ss ««»'Kei a.,-K.ö s'ugèæâssali fhuHárahovs« λ :: K54^te«g&amp;4â*$al vais ajsm Π A 4. igényponi sxennti krfcsâly. amelynek venßäk kxoskieftsadkuN eOkaat dHYnikcsdvAlgeksxJ 50 ,N> ", '*, sJ4 4 88 ' ' n ! n «8 Sft V 0/6 i'0'"k 50.08, 55 '<\ 54 <>6, 35/- 56/0 is 5/(/ röntgen peal; ΓΟΆ-χό dùtgranunta», enxelyet rez Ko sugâraàs;««d» ifcnüàmhims >. «· 1.04 Â) teugkrsksal voll: py/i/O.: 18, A 0. jgëayponï aaerœn kr/Oly, amelyaek vámsak ksîskierPxokus A4ss4Í0ülískcl''>?,,';Nj^4,íí''| 20 5/8. 8,90. B.O0, H.43. 10,84. !?56, SO.20, 50,7%-Âlk, 24,60. 25,15, 25,¾) On 26,00 iOssigea p^rddirsilîck» iôisgïsixixb;'.:;. axsrlyd -vx Ko sagkrsdoNkti: (IMlämOpsyx 2, ··.· /54 ,l,| Ix'ssigà.vxàss;;! v«H îîV'Sn··:; îO A '> igt'nyy,^;· 5.,y?ssUí krisîah, «ηχ.4>fsA vs-xiak karitkieAssOküs csüesi0 d42n4dÀNXôgek;4S 24 ' « _ (8 60 '< ν' 'p XX «' tii >'' 2 ok '>0<N >4 «> ^5('νθ3 (\ iiUipiOiYäk so d*&amp;£o)tnmkvtft, '>roilua rèz K« NiîprK&amp;ssâii îkiilkiivOxossî; o ~ lyS# .4|sfempsr«4^l v<>k jmsrv®, 2<). N V V"i iS XiiksN,»!\ Xl'vsiNi\v S tox ks tkic·' Ό \vs V S,\s xhî’rïk><'N tAk" >«' 7.80, 15.18. Ï.2.78. 16.50, 10,83, 19.20 OkOe, 3<a20. 21.20, 24,52, 35.68 *s 20, "8 töm gen sx;sOs4s&amp;kcsO 4iag«aä»ife8»,.«Jtse.l^t réí K«3t-8»gárs:á^fc OxOkböl^AN? ·' ~ 5,54 Λ) os&amp;agáraásfeiai vols, nyifsw, ||. A 9 ijvoVôïœt Nics-mii kSîNSâï. s x,kn,k n *o«A k.nalct?nNXîatu8 cnOcvís OsHhAvsii/MgAssil 3ό 2.80, 0,86, 7,88. Π.60, 13Ä 44¾ 47,46. 25.40, 2*3* ès 25/4 sviätge« peiOiHksksOO to^nimhasi, .smclyes K« Nxigá-váNVíli IOPIIIssOsísssa A 1.44 vs>0 nyerve. 22. Λ 9. i&amp;iny&amp;'M Nm«íílt kxsNS;ky, g«nd>nek karxíkten^xtikuN csocsas OílTrakcxos^ögekínJ 50 5.55 O>8. so.ísS 0.70, (4,84. si» 95 s A'8 /7'6· "',0'. 55 5'' s'n 5'svn x.'x/ev x'O.ík: :o íisagvatRmhaa. amelyet rex Ktt\ap?eápál( (h«iK*8\no.w . \* os.x-agxss.i.v'jal v$>ät ϋ',,χχΐ·· 23. Λ ') ..enrO ''ttfuív. αα»«>ΐκ'χ '»üwk karaktctisctikux cxKvas <íOO\'5kvx«vóy.>4,sx-l 2«6 5,l‘k .0,60 >Λί5\_ n,S \ M 5x 15-60, 1;<U6 Λ\"2 . «0 04, 3 3,Ko 235>0. .'4,3' 0"» 3 ' J4 mAges pt, Λ t 0<κ»αν Ka ír««' «' kt M.cKJt'.N' (Xt '.» ' hcNs ' '4 V ?χ-»χλ<,\\' v'« H)t:rvc. 24. A 6. ig3t;x :>o«s :«criau lÄ sasdvaek vasait!« kantkóriszákiis csíksai dOíVakdásAvgeksk! 20 of >M> 6,22 ; íi.56, s0.42. 14,04, 1-4.64 IS,30, 16.40. 10,62, 22,12 «s 26,42 txli»tg«t ixwdiífcakció th.igraxt«ttty,n, ,mu-Kxx 4·,' ka {AtgBtítíxxslt Uxkxfkxv'x: ) 1.34 Λ ! Öcsit sáraa^i '< »4; ever, o 2S \ o 'c.n.p.va s. '««*6 *«*t d\ ii>sx',vt"'K vamuk katakt*".}N cwev*} >t'Úí<tkxvx\ geksiel 2a ? k<\ \a3. íj π 00, 14 ak 1 x?6, lt> So. 23.«Xk 23,54. 24.00 es 2a.5a samgetä p>>s<Miakató fegiasmfesaj.smgifel $aÄskms λ ···· 1.54 À) beawgàns&amp;ml vök nyerve. 26. Λ *k jgcsv|xoy χχ-nr.a krt?x0>\ <tntviys«vk 'awá kaxtkx'tavttkas «.»sxao d40,iv.'H>\,-ogekvv: k ,.í| 3,.4 \,ρ,Ν i I S4 40, 5<'> kk i \í>4 2 : '; :>!!. 2'"x CS 34,2¾ {t-iXC.tt gvxkig-ík Χ-Λ <küKf!im«îb;îo, amelyet t\k Ka sagátkssaalí (ixdkrakxx' >, -· 1,54 A) be-tucarsásNai vak ttyerve.
  2. 27. Αχ] kikikitaa at«dy {«rttlma»» ηλ 1··6. tgiß^mok bémtelyske saerimi $3^. xssaak sóját vagy aattak kristályát, 25. 0>6gys,acr, amely ttm&amp;lsö&amp;zxás%&amp; t'&amp; Igéaypontók bármelyike. szmmi vegyületet vagy aneak sóját vagy mtisk kmtályát akt4v alkoíérésykést 30: Ä Ó4>. sgàaytX5biOk:4?às«lfiksî szérlsk vagpifek ;yggy ttsäSÄ va^f-«tasá: iklkaaaáklksga.gYág.ysatatxtíÍ::
  3. 20.. Cívógyxxfe'.'ca *.ο»η*\«'u «0, tavi" kmahoj«^ a.t i t* txntlok l- emel' :k>" ykgviklsí: vagy í«mak agát. vagy tarnak Mi#yat év gyógysmévzaíHeg ÄsptlbaM kaaioaóMyxgík; 33. A 26. ig&amp;typoMi ^*ksti:;p§g>X**3v *2 i-fx igéaypakkÉésâmîviylka igàsyiiisaîai: xivdaú vaîgyifct varay tmaak sója vagy aaaak kristálya vagy a 30.. Igénypont svedao gyágwesésveo koasíx^kkO ieihassvnálávra hsía;g»ég kexeléséken, -8^«ilM®yÄtp«rfxmk«iöja oki« a««dy katsgvégiscg Asl kiafc käpyÄ»li«lis« ífealt Mxsgyaudy keledet AxiM»á* lapcríuakciá kísér 32. A 28. lyáavp xit »eráatgyógy-wt. »r 1-6. igepypaaiak LxiranOySkc tgcayptniiok xxennti vegyük^ yggy :':p5#| Äki: vagy saîxA kîkîàiy;· \ agy .a 30. sgésyjxna sbesiíal gyx>gyx;íefé3xek kOPlpö:Ä&amp;l6: ipMóssxpállooi: i klpipíOiiléi'aiv bclfepèf te«ï&amp;l3pg: blkiisaéliaéîp, Âvtmasfâsik asggsÍ6Bgaéí&amp;:; vagy gyog yxier f « .asvstesx: i a AgyOxcvèïv . 33. a 32. igéisypisas maiaa «iyagyssçv ydgyùlci «.sgy a«tiak sûja vagy aa«sk kristálya vsgy v s îï-n et» Wx\>X' <0 53' îx.<>„( -N«» ,t ,4 , «K \{ ,m v,<a-X',i ,< ' vtsg ,->x y-xk m> H» k vastiftl'èl ràk. pr.>>zt&amp;ta râk, aidé s&amp;k, gyeatot rák. p«cfes?t»k rák, eßdömctü&amp;li* fàk.. vexe fák. li.gOvXxX'tOana gxtvhyxaa, yAaafivgp ;3x, xvy,ameh rák, ay^k-'x» ', ív, ;vp;svv.-i.i' 0 c,t«, ««»'«na. xUxlc 'st(X>v>iVOtms. iAvssssswaso „ a ' xst ' X X »f ' *vt ' » K ' M " >k
HUE13743985A 2012-01-31 2013-01-30 Piridon származék HUE031624T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012017971 2012-01-31
US201261746039P 2012-12-26 2012-12-26

Publications (1)

Publication Number Publication Date
HUE031624T2 true HUE031624T2 (hu) 2017-07-28

Family

ID=48905312

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13743985A HUE031624T2 (hu) 2012-01-31 2013-01-30 Piridon származék

Country Status (31)

Country Link
US (1) US8933103B2 (hu)
EP (1) EP2810937B1 (hu)
JP (1) JP6006241B2 (hu)
KR (1) KR102078530B1 (hu)
CN (1) CN104185627B (hu)
AU (1) AU2013216006B2 (hu)
BR (1) BR112014018702B1 (hu)
CA (1) CA2863515C (hu)
CO (1) CO7071126A2 (hu)
CY (1) CY1118656T1 (hu)
DK (1) DK2810937T3 (hu)
ES (1) ES2617484T3 (hu)
HK (1) HK1203504A1 (hu)
HR (1) HRP20170303T1 (hu)
HU (1) HUE031624T2 (hu)
IL (1) IL233863A (hu)
LT (1) LT2810937T (hu)
MX (1) MX351812B (hu)
MY (1) MY165215A (hu)
NZ (1) NZ627586A (hu)
PH (1) PH12014501719A1 (hu)
PL (1) PL2810937T3 (hu)
PT (1) PT2810937T (hu)
RS (1) RS55728B1 (hu)
RU (1) RU2632885C2 (hu)
SG (1) SG11201404505PA (hu)
SI (1) SI2810937T1 (hu)
SM (1) SMT201700065B (hu)
TW (1) TWI537259B (hu)
WO (1) WO2013115280A1 (hu)
ZA (1) ZA201405486B (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013162061A1 (ja) * 2012-04-26 2013-10-31 第一三共株式会社 二環性ピリミジン化合物
JP6493218B2 (ja) * 2013-11-08 2019-04-03 小野薬品工業株式会社 ピロロピリミジン誘導体
WO2015077375A1 (en) 2013-11-20 2015-05-28 Signalchem Lifesciences Corp. Quinazoline derivatives as tam family kinase inhibitors
CN110156770B (zh) 2013-11-27 2022-10-04 圣诺康生命科学公司 作为tam族激酶抑制剂的氨基吡啶衍生物
CA2946538A1 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
TWI723572B (zh) * 2014-07-07 2021-04-01 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
WO2016183071A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Hetero-tricyclic compounds and their use for the treatment of cancer
US9708333B2 (en) 2015-08-12 2017-07-18 Incyte Corporation Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
JP6885390B2 (ja) 2016-02-26 2021-06-16 小野薬品工業株式会社 Ａｘｌ阻害剤と免疫チェックポイント阻害剤とを組み合わせて投与することを特徴とする癌治療のための医薬
RS65129B1 (sr) 2016-03-28 2024-02-29 Incyte Corp Jedinjenja pirolotriazina kao inhibitori tam
CN108250200A (zh) * 2016-12-28 2018-07-06 中国科学院上海药物研究所 一种具有Axl抑制活性的化合物及其制备和应用
JP7156287B2 (ja) 2017-08-23 2022-10-19 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含むがん治療剤
EP3988552A1 (en) 2017-09-27 2022-04-27 Incyte Corporation Salts of pyrrolotriazine derivatives useful as tam inhibitors
WO2019074116A1 (ja) 2017-10-13 2019-04-18 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
AU2019212959A1 (en) * 2018-01-29 2020-09-17 Capulus Therapeutics, Llc SREBP inhibitors comprising a 6-membered central ring
SI3762368T1 (sl) 2018-03-08 2022-06-30 Incyte Corporation Aminopirazin diolne spojine kot zaviralci PI3K-y
AU2019293618A1 (en) 2018-06-29 2021-02-18 Incyte Corporation Formulations of an AXL/MER inhibitor
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
TWI840378B (zh) * 2018-07-04 2024-05-01 日商第一三共股份有限公司 二芳基吡啶衍生物之製造方法
CA3109891A1 (en) * 2018-08-24 2020-02-27 Nanjing Transthera Biosciences Co., Ltd. Quinoline derivative inhibitor: tam, ntrk, and csf1r kinases
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
WO2021046515A1 (en) 2019-09-06 2021-03-11 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease
CN112625026B (zh) * 2019-09-24 2022-09-09 药捷安康(南京)科技股份有限公司 Tam家族激酶抑制剂的喹啉衍生物
MX2022003671A (es) 2019-09-27 2022-04-25 Univ Texas Inhibidores de proteina cinasa i de interaccion con receptores para el tratamiento de enfermedades.
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
BR112022010082A2 (pt) * 2019-11-26 2022-08-30 Univ Texas Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, uso do composto e uso da composição farmacêutica
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JPWO2022220227A1 (hu) * 2021-04-14 2022-10-20

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1176956T3 (da) * 1999-05-07 2008-05-26 Encysive Pharmaceuticals Inc Carboxylsyrederivater, som inhiberer bindingen af integriner til deres receptorer
EP1136485A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo Aminophenyl pyrimidone derivatives
AU2003223172A1 (en) 2002-02-12 2003-09-04 Quark Biotech, Inc. Use of the axl receptor for diagnosis and treatment of renal disease
CA2621503C (en) 2005-09-07 2014-05-20 Rigel Pharmaceuticals, Inc. Triazole derivatives useful as axl inhibitors
WO2007057399A2 (en) 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer with indole derivatives
SI1959955T1 (sl) 2005-12-05 2011-02-28 Pfizer Prod Inc Postopek zdravljenja abnormalne celične rasti
ES2562428T3 (es) 2005-12-15 2016-03-04 Rigel Pharmaceuticals, Inc. Inhibidores de cinasa y sus usos
EP1900727A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Aminopyridine derivatives as kinase inhibitors
WO2008045978A1 (en) 2006-10-10 2008-04-17 Rigel Pharmaceuticals, Inc. Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
ES2460894T3 (es) 2006-12-29 2014-05-14 Rigel Pharmaceuticals, Inc. Triazoles sustituidos con heteroarilo policíclico útiles como inhibidores de Axl
ES2672172T3 (es) 2006-12-29 2018-06-12 Rigel Pharmaceuticals, Inc. Triazoles N3-heteroarilsustituidos y triazoles N5-heteroarilsustituidos útiles como inhibidores de Axl
CA2710043C (en) 2006-12-29 2016-02-09 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2008083356A1 (en) 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. Substituted triazoles useful as axl inhibitors
ES2404668T3 (es) 2006-12-29 2013-05-28 Rigel Pharmaceuticals, Inc. Triazoles sustituidos con arilo bicíclico puenteado y heteroarilo bicíclico puenteado, útiles como agentes inhibidores del axl
CA2682733A1 (en) 2007-04-13 2008-10-23 Supergen, Inc. Axl kinase inhibitors
GB0713259D0 (en) 2007-07-09 2007-08-15 Astrazeneca Ab Pyrazine derivatives 954
JP2010533159A (ja) * 2007-07-09 2010-10-21 アストラゼネカ アクチボラグ 化合物９４７
WO2009024825A1 (en) 2007-08-21 2009-02-26 Astrazeneca Ab 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
AU2008315746A1 (en) * 2007-10-25 2009-04-30 Astrazeneca Ab Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
RU2010120536A (ru) * 2007-10-25 2011-11-27 Астразенека Аб (Se) Производные пиридина и пиразина, полезные для лечения клеточных проферативных расстройств
SI2205592T1 (sl) * 2007-10-26 2013-09-30 Rigel Pharmaceuticals, Inc. Triazoli substituirani s policikličnim arilom in triazoli substituirani s policikličnim heteroarilom uporabni kot Axl inhibitorji
CN101917994A (zh) 2007-11-02 2010-12-15 詹森药业有限公司 Cfms抑制剂用于治疗或预防骨癌以及与骨癌相关的骨丢失和骨痛的用途
KR101596527B1 (ko) 2008-01-23 2016-02-22 브리스톨-마이어스 스큅 컴퍼니 ４-피리디논 화합물 및 암에 대한 그의 용도
WO2009094427A1 (en) 2008-01-23 2009-07-30 Bristol-Myers Squibb Company 4-pyridinone compounds and their use for cancer
CA2718538A1 (en) 2008-04-16 2009-10-22 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Quinoline derivatives as axl kinase inhibitors
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
WO2009138799A1 (en) 2008-05-14 2009-11-19 Astex Therapeutics Limited Therapeutic uses of 1-cycl0pr0pyl-3 - [3- ( 5 -morpholin- 4 -ylmethyl- 1h-benz0imidaz0l- 2 -yl) -lh-pyrazol-4-yl] -urea
PT2328888E (pt) 2008-07-09 2013-01-29 Rigel Pharmaceuticals Inc Triazóis bicíclicos em ponte substituídos com heteroarilos úteis como inibidores axl
WO2010005876A2 (en) 2008-07-09 2010-01-14 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
US20100204221A1 (en) 2009-02-09 2010-08-12 Hariprasad Vankayalapati Pyrrolopyrimidinyl axl kinase inhibitors
MX2011011326A (es) * 2009-04-27 2012-02-13 Elan Pharm Inc Antagonistas de piridinona de las integrinas alfa-4.
EP2311809A1 (en) 2009-10-16 2011-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinolinyloxyphenylsulfonamides
JP5970003B2 (ja) 2011-03-04 2016-08-17 ローカス ファーマシューティカルズ インコーポレイテッド アミノピラジン化合物

Also Published As

Publication number Publication date
SG11201404505PA (en) 2014-10-30
PT2810937T (pt) 2017-03-03
US20130281428A1 (en) 2013-10-24
JPWO2013115280A1 (ja) 2015-05-11
RS55728B1 (sr) 2017-07-31
CY1118656T1 (el) 2017-07-12
WO2013115280A1 (ja) 2013-08-08
HRP20170303T1 (hr) 2017-04-21
MY165215A (en) 2018-03-09
KR20140117439A (ko) 2014-10-07
BR112014018702A8 (pt) 2017-07-11
CN104185627A (zh) 2014-12-03
JP6006241B2 (ja) 2016-10-12
AU2013216006A1 (en) 2014-08-28
CA2863515A1 (en) 2013-08-08
CO7071126A2 (es) 2014-09-30
CN104185627B (zh) 2018-01-12
TW201335148A (zh) 2013-09-01
MX2014009246A (es) 2014-10-14
PH12014501719B1 (en) 2014-11-10
SI2810937T1 (sl) 2017-01-31
IL233863A (en) 2017-08-31
AU2013216006B2 (en) 2017-06-08
BR112014018702B1 (pt) 2021-12-14
EP2810937B1 (en) 2016-11-30
EP2810937A1 (en) 2014-12-10
HK1203504A1 (en) 2015-10-30
IL233863A0 (en) 2014-09-30
MX351812B (es) 2017-10-27
RU2632885C2 (ru) 2017-10-11
SMT201700065B (it) 2017-03-08
ZA201405486B (en) 2015-11-25
RU2014135401A (ru) 2016-03-20
EP2810937A4 (en) 2015-07-22
US8933103B2 (en) 2015-01-13
ES2617484T3 (es) 2017-06-19
DK2810937T3 (en) 2017-03-13
KR102078530B1 (ko) 2020-02-18
NZ627586A (en) 2016-08-26
PH12014501719A1 (en) 2014-11-10
BR112014018702A2 (hu) 2017-06-20
LT2810937T (lt) 2017-02-10
TWI537259B (zh) 2016-06-11
CA2863515C (en) 2018-02-27
PL2810937T3 (pl) 2017-07-31

Similar Documents

Publication Publication Date Title
HUE031624T2 (hu) Piridon származék
KR102181915B1 (ko) Trka 키나아제 억제제로서 n-피롤리디닐, n&#39;-피라졸릴-우레아, 티오우레아, 구아니딘 및 시아노구아니딘 화합물
RU2743074C2 (ru) Соединения, активные по отношению к бромодоменам
JP6086516B2 (ja) テトラヒドロピラニルメチル基を有するピリドン誘導体
AU2014240388B2 (en) Substituted 7-azabicycles and their use as orexin receptor modulators
EA029757B1 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CN106715415A (zh) 3‑氨基‑1,5,6,7‑四氢‑4h‑吲哚‑4‑酮
WO2013162061A1 (ja) 二環性ピリミジン化合物
CN113038948B (zh) 杂环化合物
EA010298B1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
AU2014304308B2 (en) Piperidine and azepine derivatives as prokineticin receptor modulators
WO2017034377A1 (en) Pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms)
EA047234B1 (ru) Иммуномодуляторы, композиции и способы с их использованием
BR112017000242B1 (pt) Composto, cristal, inibidor de axl, medicamento, composição farmacêutica, e, uso de um composto
KR20150001353A (ko) Fms 키나아제 저해 활성을 갖는 피리미딘 유도체